Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study
- PMID: 10206072
- DOI: 10.1023/a:1006179511178
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study
Abstract
Aim: To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment.
Methods: The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment.
Results: The non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment.
Conclusion: Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients.
Similar articles
-
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.Clin Cancer Res. 1997 Apr;3(4):593-600. Clin Cancer Res. 1997. PMID: 9815725 Clinical Trial.
-
Cytological evaluation of biological prognostic markers from primary breast carcinomas.Breast Cancer Res Treat. 1997 May;44(1):65-74. doi: 10.1023/a:1005717924761. Breast Cancer Res Treat. 1997. PMID: 9164679 Clinical Trial.
-
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.Cancer. 2000 Dec 1;89(11):2145-52. Cancer. 2000. PMID: 11147583
-
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.J Clin Oncol. 1999 Oct;17(10):3058-63. doi: 10.1200/JCO.1999.17.10.3058. J Clin Oncol. 1999. PMID: 10506600
-
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.Breast Cancer Res. 2001;3(6):361-4. doi: 10.1186/bcr323. Epub 2001 Oct 1. Breast Cancer Res. 2001. PMID: 11737886 Free PMC article. Review.
Cited by
-
Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.Breast Cancer Res Treat. 2022 May;193(1):151-159. doi: 10.1007/s10549-022-06548-w. Epub 2022 Feb 28. Breast Cancer Res Treat. 2022. PMID: 35229238
-
Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820928435. doi: 10.1177/1533033820928435. Technol Cancer Res Treat. 2020. PMID: 32508292 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer.Cancer Res Treat. 2018 Oct;50(4):1418-1432. doi: 10.4143/crt.2017.552. Epub 2018 Jan 24. Cancer Res Treat. 2018. PMID: 29361816 Free PMC article.
-
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.Int J Clin Oncol. 2016 Apr;21(2):254-261. doi: 10.1007/s10147-015-0897-1. Epub 2015 Sep 4. Int J Clin Oncol. 2016. PMID: 26338270
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous